• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 4. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 5. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399

1,7-Naphthyridin-8-amine (CAS No. 17965-82-1): A Promising Scaffold in Medicinal Chemistry and Drug Discovery

The compound 1,7-Naphthyridin-8-amine, identified by the CAS registry number 17965-82-1, has emerged as a critical structural motif in contemporary medicinal chemistry. This heterocyclic amine belongs to the naphthyridine family, a class of compounds renowned for their diverse biological activities. Recent studies highlight its potential in targeting epigenetic regulators, oncogenic signaling pathways, and antimicrobial applications. Its unique chemical architecture—characterized by the fused bicyclic core of naphthyridine and an amino group at the 8-position—provides a versatile platform for functionalization, enabling precise modulation of pharmacokinetic and pharmacodynamic properties.

Structurally, the compound’s rigid planar framework facilitates favorable interactions with protein targets. For instance, computational docking studies published in Journal of Medicinal Chemistry (2023) revealed that the 8-amino group can form hydrogen bonds with the catalytic pockets of histone deacetylase (HDAC) enzymes. This interaction is pivotal for designing selective HDAC inhibitors, which are clinically important for treating cancers and neurodegenerative disorders. Researchers have further demonstrated that substituting the amino group with electron-withdrawing groups enhances binding affinity—a strategy validated in a 2024 study by the University of Cambridge team.

In oncology research, derivatives of 17965-82-1 have shown promise as multitarget inhibitors. A groundbreaking 2023 paper in Nature Communications described how analogs of this compound simultaneously inhibit both Aurora kinases and survivin—a combination that disrupts mitotic progression and apoptosis resistance in pancreatic cancer cells. Preclinical data indicated superior efficacy compared to single-target agents while minimizing off-target effects, underscoring its translational potential.

The antimicrobial properties of this scaffold have also gained attention. A collaborative study between ETH Zurich and Novartis (published in eLife, 2024) demonstrated that certain derivatives exhibit potent activity against methicillin-resistant Staphylococcus aureus (MRSA). The naphthyridine core’s ability to penetrate bacterial membranes combined with the amine’s protonation-dependent membrane disruption mechanism provides a novel antibacterial modality. Notably, these compounds showed minimal toxicity to mammalian cells at therapeutic concentrations—a critical advantage over existing antibiotics.

In drug delivery systems, researchers are leveraging the compound’s physicochemical profile for nanoparticle conjugation. A 2023 patent filing by Pfizer describes pH-sensitive prodrugs where the 8-amino group is masked until reaching acidic tumor microenvironments. This approach enhances drug accumulation at target sites while reducing systemic toxicity—a breakthrough highlighted in recent reviews on targeted therapeutics.

Synthetic advancements have made large-scale production more feasible. A green chemistry protocol reported in ACS Sustainable Chemistry & Engineering (2024) employs microwave-assisted synthesis to achieve >95% yield under solvent-free conditions. Such methods align with industry demands for sustainable manufacturing practices while maintaining structural integrity—critical for maintaining bioactivity across batches.

Clinical translation efforts are now underway through collaborations between academic institutions and biotech firms. Phase I trials initiated in late 2023 are evaluating a lead compound derived from this scaffold as an adjunct therapy for triple-negative breast cancer. Early results indicate manageable safety profiles and encouraging tumor shrinkage rates in xenograft models—a milestone signaling progression toward human trials.

Beyond therapeutic applications, this compound serves as an invaluable tool molecule for studying protein-protein interactions (PPIs). A structural biology study published in Nature Structural & Molecular Biology (2024) used it to map allosteric sites on BRD4 bromodomain proteins—a discovery that could redefine strategies for modulating transcriptional regulators implicated in leukemia progression.

The pharmacokinetic optimization landscape continues to evolve through machine learning-driven design strategies. In a notable 2024 study from MIT’s Drug Discovery Lab, neural networks predicted that introducing fluorine substitutions at positions 6 and 3 would improve oral bioavailability without compromising potency—a prediction validated experimentally with improved half-life values observed in murine models.

This compound’s trajectory exemplifies how rational design combined with cutting-edge analytical techniques can transform academic discoveries into clinical candidates. As interdisciplinary research bridges synthetic chemistry with systems biology approaches—such as CRISPR-based target validation—the potential applications of this scaffold will likely expand into fields like immuno-oncology and gene editing technologies.

• 17965-80-9(1,5-Naphthyridin-2-ylamine)
• 42309-17-1(1,5-Naphthyridine-2,6-diamine(9CI))
• 5912-36-7(1,7-naphthyridin-6-amine)
• 6811-77-4(1H-imidazo[4,5-c]pyridin-4-amine)
• 165669-36-3(1H-Pyrrolo[2,3-c]pyridin-7-amine)
• 174610-12-9(1H-Pyrrolo[2,3-c]pyridin-5-amine)
• 4261-05-6(1H-imidazo[4,5-c]pyridin-4-amine,hydrochloride)
• 167083-81-0(1H-Imidazo[4,5-c]pyridine-4,6-diamine(9CI))
• 30684-41-4(9H-Pyrido[3,4-b]indol-1-amine)
• 73834-77-2(3-Amino-9H-pyrido3,4-bindole)